Jay Lichter News Today

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) Director Jay Lichter sold 1,500,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $82,125,000.00. Following the sale, the director now directly owns 633,673 shares of the company’s stock, […]

Cue Health notified employees that everyone, including its leadership, will be laid off as it closes operations this Friday.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

A tune-up

Family project

When it rains

Arialys Therapeutics Inc. launched this month with $58 million in seed funding, an experimental compound it is developing for autoimmune encephalitis and autoimmune psychosis, and high aspirations for its field. “Yes, I want to treat these patients, I want these patients to have a better life. But I also want drug discovery and development folks to think differently about discovering new drugs for the CNS,” Jay Lichter told BioWorld.

This disease can, at the very least, help researchers to “identify” the floodgates to definitive tests and therapies for complex psychological and neurological diseases, expert says.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

The San Diego Angel Conference, a program at the University of San Diego’s Knauss School of Business, is launching a fund for its sixth angel conference program.